ArticleFrontiers in cellular and infection microbiology2016
Intramacrophage Survival for Extracellular Bacterial Pathogens: MgtC As a Key Adaptive Factor.
Article in Frontiers in cellular and infection microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Glycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections.Bioactive materials · 2026Article
- Article
- Harnessing immunopeptidomics for next-generation vaccines against intracellular bacterial pathogens.Molecular biology reports · 2025Review
- Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.Antimicrobial agents and chemotherapy · 2025Article
- Nanosensor-Enabled Detection and Identification of Intracellular Bacterial Infections in Macrophages.Biosensors · 2024Article
- Contribution of intramacrophage stages to Pseudomonas aeruginosa infection outcome in zebrafish embryos: insights from mgtC and oprF mutants.Scientific reports · 2024Article
- Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes.Frontiers in microbiology · 2024Review
- Impact of MgtC on the Fitness ofPathogens (Basel, Switzerland) · 2023Article
- Repurposing Inhibitors of Phosphoinositide 3-kinase as Adjuvant Therapeutics for Bacterial Infections.Frontiers in antibiotics · 2023Article
- A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.Journal of nanobiotechnology · 2022Review
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Coinfections and their molecular consequences in the porcine respiratory tract.Veterinary research · 2020Review
- Efficacy of Levofloxacin Loaded Nonionic Surfactant Vesicles (Niosomes) in a Model ofAdvances in pharmacological and pharmaceutical sciences · 2020Article
- Synthetic hydrophobic peptides derived from MgtR weaken Salmonella pathogenicity and work with a different mode of action than endogenously produced peptides.Scientific reports · 2019Article
- Killing from the inside: Intracellular role of T3SS in the fate of Pseudomonas aeruginosa within macrophages revealed by mgtC and oprF mutants.PLoS pathogens · 2019Article
- Activity of a Synthetic Peptide Targeting MgtC onFrontiers in cellular and infection microbiology · 2019Article
- How Viral and Intracellular Bacterial Pathogens Reprogram the Metabolism of Host Cells to Allow Their Intracellular Replication.Frontiers in cellular and infection microbiology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.